Rheumatoid Arthritis Clinical Trial
— NIMRAOfficial title:
Novel Imaging Markers for Rheumatoid Arthritis
NCT number | NCT01773681 |
Other study ID # | UCBCelltech |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | October 2013 |
Est. completion date | March 2018 |
Verified date | November 2018 |
Source | University of California, San Francisco |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this study is to use magnetic resonance imaging (MRI) and high-resolution
peripheral quantitative computed tomography (HR-pQCT) techniques to look at the damage and
disease activity progression in the hand and wrist joints of patients with rheumatoid
arthritis.
The central hypothesis is that ongoing erosions and cartilage loss in rheumatoid arthritis
are due to persistent inflammation, which is poorly detected by clinical examination and
markers of systemic inflammation.
Status | Completed |
Enrollment | 30 |
Est. completion date | March 2018 |
Est. primary completion date | March 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
The inclusion criteria for all patients to be enrolled are: - RA by 2010 ACR classification criteria - Age = 18 years at enrollment - Ability to give consent and follow the study protocol - Prednisone permitted in doses =10 mg daily - Women of reproductive potential must agree to use an acceptable method of birth control during treatment Additional inclusion criteria for group I: - DAS28 = 3.2 during the last 2-months prior to the baseline visit - On MTX at a stable dose for > 8 weeks prior to the baseline visit - No biologic therapy during the past 6-months prior to the baseline visit - No anticipated biologic therapy Additional inclusion criteria for group II: - DAS28 > 3.2 - No biologic therapy during the past 6-months prior to the baseline visit - Scheduled to initiate anti-TNF therapy using CIMZIA Exclusion Criteria for all patients to be enrolled are: - Any psychiatric disorder that prevents the subject from providing informed consent - Inability or unwillingness to follow the protocol - Estimated glomerular filtration rate (eGFR, calculated based on serum creatinine) < 60 ml/min/1.72m2 - Known allergy or hypersensitivity to any study products (including gadolinium) - History of injury or surgery of the wrist and hand to be scanned - Inability to place non-dominant hand appropriately for imaging - History of claustrophobia; inability to tolerate MRI and other contraindication of MRI - Pregnancy or breast-feeding - Diabetes mellitus requiring insulin therapy - Prednisone dose > 10 mg/day (or equivalent dose of another corticosteroid) within 1 month of baseline visit - Any investigational agent within the earlier of 4 weeks or 5 half-lives prior to randomization - Any biologic therapy within 6-month prior to the baseline visit - Any condition or treatment, which in the opinion of the investigator, places the subject at an unacceptable risk as a participant in the study Additional exclusion criteria for Group II: - Chronic or persistent infection including but not limited to human immunodeficiency virus [HIV], hepatitis B, hepatitis C, listeriosis, TB, or other opportunistic infection) - Active infection or severe infections requiring hospitalization or treatment with intravenous (IV) antibiotics, IV antivirals, or IV antifungals within 30 days prior to baseline visit, or oral antibiotics, oral antivirals, or oral antifungals within 14 days prior to baseline visit - Receipt of a live vaccine within 4 weeks prior to baseline visit - History of malignancy within the past 5 years other than treated localized carcinoma in situ of the cervix or adequately treated non-metastatic squamous or basal cell skin carcinoma |
Country | Name | City | State |
---|---|---|---|
United States | UCSF - China Basin Imaging Center | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Francisco |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To better understand how Cimzia and methotrexate affect the damage and disease activity progression in the hand and wrist of patients with rheumatoid arthritis | up to 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04226131 -
MusculRA: The Effects of Rheumatoid Arthritis on Skeletal Muscle Biomechanics
|
N/A | |
Completed |
NCT04171414 -
A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT02833350 -
Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)
|
Phase 2 | |
Completed |
NCT04255134 -
Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)
|
Phase 4 | |
Recruiting |
NCT05615246 -
Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
|
||
Completed |
NCT03248518 -
Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases
|
N/A | |
Completed |
NCT03514355 -
MBSR in Rheumatoid Arthritis Patients With Controlled Disease But Persistent Depressive Symptoms
|
N/A | |
Recruiting |
NCT06005220 -
SBD121, a Synbiotic Medical Food for RA Management
|
N/A | |
Recruiting |
NCT05451615 -
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
|
Phase 3 | |
Completed |
NCT05054920 -
Eccentric Versus Concentric Exercises for Rotator Cuff Tendinopathy in Patients With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT02037737 -
Impact and Use of Abatacept IV for Rheumatoid Arthritis in Real Life Setting
|
N/A | |
Recruiting |
NCT04079374 -
Comparative Efficacy, Safety and Immunogenicity Study of Etanercept and Enbrel
|
Phase 3 | |
Completed |
NCT02504268 -
Effects of Abatacept in Patients With Early Rheumatoid Arthritis
|
Phase 3 | |
Recruiting |
NCT05496855 -
Remote Care in People With Rheumatoid Arthritis
|
N/A | |
Completed |
NCT05051943 -
A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
|
||
Recruiting |
NCT06031415 -
Study of GS-0272 in Participants With Rheumatoid Arthritis
|
Phase 1 | |
Recruiting |
NCT06103773 -
A Study of Single and Multiple Oral Doses of TollB-001
|
Phase 1 | |
Completed |
NCT05999266 -
The Cartilage and Muscle Thickness on Knee Pain in Patients With Rheumatoid Arthritis
|
||
Recruiting |
NCT05302934 -
Evaluation of the PHENO4U Data Platform in Patients Undergoing Total Knee Arthroplasty
|
||
Recruiting |
NCT04169100 -
Novel Form of Acquired Long QT Syndrome
|
Phase 4 |